Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protara TherapeuticsTARA -2.73%32 Current Ratio is 15.69 as of Mar. 2026, which is 0% below its 10-year median of 15.70. GuruFocus rates TARA with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Protara Therapeutics ranks better than 87.46% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Protara Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 15.69.
Protara Therapeutics has a current ratio of 15.69. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Protara Therapeutics's Current Ratio or its related term are showing as below:
TARA'
s Current Ratio Range Over the Past 10 Years
Min: 0.23 Med: 15.7 Max: 58.13
Current: 15.69
During the past 8 years, Protara Therapeutics's highest Current Ratio was 58.13. The lowest was 0.23. And the median was 15.70.
TARA's Current Ratio is ranked better than 87.46% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs TARA: 15.69
Protara Therapeutics (NAS:TARA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Protara Therapeutics Current Ratio Related Terms
Protara Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Protara Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TARA vs TRDA, ACIU, OBIO: Current Ratio Comparison
For the Biotechnology subindustry, Protara Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protara Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Protara Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protara Therapeutics (TARA) has a Current Ratio of 15.69 as of Mar. 2026. This is near median its historical median of 15.70. Over the past decade, Protara Therapeutics' Current Ratio has ranged from 0.23 to 58.13. According to the industry distribution chart, Protara Therapeutics ranks #177 out of 1411 companies in the Biotechnology industry, placing it in the top 12.5%.
Is Protara Therapeutics' Current Ratio too high?
Protara Therapeutics' current Current Ratio of 15.69 is near median its 10-year median of 15.70. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 58.13. The Biotechnology industry median Current Ratio is 3.85. Protara Therapeutics' value of 15.69 is 307.5% above this industry median. Based on the distribution chart, Protara Therapeutics ranks #177 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protara Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Current Ratio compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, Protara Therapeutics ranks #177 out of 1411 companies for Current Ratio. This places Protara Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.85. Protara Therapeutics' value of 15.69 is 307.5% above this benchmark. Historically, Protara Therapeutics' own Current Ratio has ranged from 0.23 to 58.13 over the past decade. While the company's 10-year median is 15.70 vs. the industry median of 3.85, Protara Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protara Therapeutics's current Current Ratio of 15.69 is 307.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protara Therapeutics's current Current Ratio is 15.69, which is near median its own 10-year median of 15.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (TARA) has a current Current Ratio of 15.69. The current Current Ratio is 15.69, which is near median its 10-year median of 15.70 and 307.5% above the Biotechnology industry median of 3.85. Protara Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Protara Therapeutics (TARA), the current Current Ratio is 15.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
32GF Score
Get the complete analysis for TARA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARA has been successfully added to your 
